Hemispherx treats first patient in clinical trial of Ampligen
Category: #health  By Nikita Chaurasia  Date: 2019-06-14
  • share
  • Twitter
  • Facebook
  • LinkedIn

Hemispherx treats first patient in clinical trial of Ampligen

Hemispherx Biopharma Inc., a US-based biopharmaceutical company recently announced having treated its first patient with Ampligen in combination with Cisplatin & Pembrolizumab, in a phase 2 ovarian cancer clinical trial.

As per credible sources, the study is evaluating Hemispherx' patented experimental drug Ampligen in combination with cisplatin and pembrolizumab, an anti-PD-1 check-point blockade therapy, under the leadership of principal investigator Robert Edwards. The study is expected to treat 45 patients. It is a second periodic ovarian cancer trial of Ampligen at University of Pittsburgh Medical Centre (UPMC).

For the record, Hemispherx Biopharma, Inc. is a pharmaceutical company, focused on R&D of therapeutics to treat multiple types of cancer. The company’s flagship product includes Ampligen and Alferon N Injection. Based on pre-clinical studies & clinical trials of Amligen, Hemispherx concluded the drug to have broad-spectrum anti-cancer & anti-viral properties. Already conducted clinical trials of Ampligen includes studies of potential treatment of cancer patients with malignant melanoma and renal cell carcinoma.

As per sources close to the matter, a phase 1/2 study was initiated approximately 3 years ago & is near completion of the phase 1 portion. The clinical outcome from initial phase 1/2 clinical trial of recurring ovarian cancer is being drafted by Dr. Edwards' team.

Dr. Edwards, chairman of gynecology services at UPMC’s Magee-Women's Hospital, Professor of Obstetrics, Gynecology & Reproductive Services at UPMC, was reported to say that the initial trial of Ampligen indicates that the drug is generally well-tolerated through intraperitoneal supervision and thus paved way for the new phase 2 study, combining Ampligen with pembrolizumab. Ampligen contains strong killer T-cell that can stay in tumor microenvironment without attracting regulatory T cells. The drug has the potential to be clinically significant by helping optimize barrier block induced tumor shrinkage.

Thomas K. Equels, CEO, Hemispherx, was reportedly quoted saying that Ovarian cancer is anticipated to kill 152,000 women this year world-wide. In the new study Hemispherx & the team at Magee-Women's Hospital of UPMC are focused on developing a life-saving therapy to meet this critical need.

Source credits: https://hemispherx.irpass.com/Hemispherx-Biopharma-Announces-First-Patient-Treated-in-Phase-2-Ovarian-Cancer-Clinical-Trial-Evalua

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia    

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More

More News By Nikita Chaurasia

Syndax Pharmaceuticals reveals data from phase 1 trial of axatilimab
Syndax Pharmaceuticals reveals data from phase 1 trial of axatilimab
By Nikita Chaurasia

According to reliable sources, Massachusetts-headquartered clinical stage biopharmaceutical company, Syndax Pharmaceuticals Inc. has revealed an updated data from its Phase 1 trial of its patent axatilimab. The company will reportedly present the dat...

Xiaomi shares drop by 7.1% after raising USD 3.9 billion in equity deal
Xiaomi shares drop by 7.1% after raising USD 3.9 billion in equity deal
By Nikita Chaurasia

Shares of Xiaomi Corporation, a Chinese multinational electronics company, witnessed a 7.1% drop during Hong Kong trading after the company secured USD 3.91 billion in fund raising which also included the city’s top-up placement. The company h...

Supercom signs a supply contract of PureSecurity EM suite in Wisconsin
Supercom signs a supply contract of PureSecurity EM suite in Wisconsin
By Nikita Chaurasia

Israel-based leading provider of advanced solutions for cybersecurity, IoT (Internet of Things) and e-Government sectors Supercom has reportedly signed a supply agreement to deliver its PureSecurity EM (Electronic Monitoring) product suite in Wiscons...